Remiges Ventures forms and manages innovative science-based companies, advancing them to Series A stage.
15
Operating
Remiges Ventures specializes in forming and managing innovative science-based companies, primarily focusing on the life sciences sector. The firm supports academic innovations, advancing portfolio companies from inception through Series A stage. Remiges typically invests in seed and Series A rounds, with occasional participation in Series B funding.
Notable portfolio companies include Cyrano Therapeutics, ENB Therapeutics, Glycomine, Immunis, Tranquis Therapeutics, and Viage Therapeutics. Remiges offers hands-on management during company formation, leveraging its team's expertise to guide product development. The firm's unique approach involves creating companies based on intellectual properties from Japanese academia and transforming them into viable commercial entities.
Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies8
Follow-on Investments2
Current Portfolio Count8
Top Investment Stages
Series A4 (40.0%)
Series B3 (30.0%)
Seed2 (20.0%)
Series C1 (10.0%)
Stage Mix
Series A 40%Series B 30%Seed 20%Series C 10%
Concentration shown as share of disclosed investments by stage.
